

Robeco BP US Premium Equities F EUR

Robeco BP US Premium Equities is an actively managed fund that invests in value stocks in the United States. The selection of these value stocks is based on fundamental analysis. The fund's objective is to achieve a better return than the index. The portfolio is consistently built from the bottom up, to exhibit attractive valuation, strong business fundamentals and improving business momentum. These companies can be large-caps, mid-caps or small-caps.



Duilio R. Ramallo CFA
Fund manager since 03-10-2005

Performance

	Fund	Index
1 m	0.91%	1.12%
3 m	4.16%	4.44%
Ytd	-2.58%	-2.84%
1 Year	1.89%	3.20%
2 Years	8.47%	10.66%
3 Years	6.72%	7.08%
5 Years	13.96%	13.47%
10 Years	9.47%	9.64%
Since 07-2009	13.17%	13.58%

Annualized (for periods longer than one year)
Note: due to a difference in measurement period between the fund and the index, performance differences may arise. For further info, see last page.

Calendar year performance

	Fund	Index
2024	16.22%	21.59%
2023	8.12%	7.88%
2022	3.00%	-1.95%
2021	33.85%	34.89%
2020	-4.39%	-5.62%
2022-2024	8.98%	8.75%
2020-2024	10.62%	10.36%

Annualized (years)

Index

Russell 3000 Value Index (Gross Total Return, EUR)

General facts

Morningstar	★★★★
Type of fund	Equities
Currency	EUR
Total size of fund	EUR 5,084,446,055
Size of share class	EUR 124,169,794
Outstanding shares	289,250
1st quotation date	28-09-2012
Close financial year	31-12
Ongoing charges	0.96%
Daily tradable	Yes
Dividend paid	No
Ex-ante tracking error limit	-
Management company	Robeco Institutional Asset Management B.V.


Sustainability profile

- Exclusions
- ESG Integration
- Voting & Engagement
- ESG Target
- Target Universe

For more information on exclusions see <https://www.robeco.com/exclusions/>

Performance

Indexed value (until 31-08-2025) - Source: Robeco



Performance

Based on transaction prices, the fund's return was 0.91%. Robeco BP US Premium Equities was more or less in line with the Russell 3000 Value Index, with stock selection adding value while sector allocation detracted from relative returns. From a stock selection perspective, the fund added most value in the industrials and materials sectors, which was mainly offset by picks in the financials and consumer staples sectors. Within industrials, manufacturer Resideo Technologies was the strongest performing holding, rising 25%. Outside of this, a collection of holdings added value in the sector (Uber, C.H. Robinson Worldwide), while avoiding names such as machinery companies Caterpillar and Deere also helped. In materials, CRH Plc was a strong performer, rising close to 19%. On the negative side to stock selection, finance holdings LPL Financial, Fidelity National Information Services and Shift4 Payments all had a lackluster month, while in consumer staples, Keurig Dr Pepper lagged. Contribution to sector allocation was also mixed, with overweight in information technology detracting from relative results, while having no exposure to utilities and overweight in healthcare added to relative returns.

Market development

US equity markets moved higher in the quieter holiday month of August, with the core S&P 500 Index higher by just over 2%. Value equities outperformed both core and growth equities across the market cap spectrum, led by small caps which outperformed mid and large caps in the month, with small-cap value returning 8.43%, as measured by the Russell 2000 Value Index.

Expectation of fund manager

Despite all the policy shifts coming out of Washington this year, with uncertainty surrounding tariffs and trade, the markets have held up relatively well. As it stands, tariffs will probably have an inflationary impact on interest rates going forward. So far, we haven't seen any expectations for earnings to come down, so if earnings growth is stable and interest rates don't get away from us, then the markets should perform reasonably well through the rest of the year. As always, we remain focused on selecting companies from the bottom-up that reflect Boston Partners' three-circle characteristics – attractive valuations, solid business fundamentals, and identifiable catalysts.

Top 10 largest positions

AbbVie entered the top ten in August, replacing Oracle.

Fund price

31-08-25	EUR	429.28
High Ytd (10-02-25)	EUR	465.01
Low Ytd (22-04-25)	EUR	378.53

Fees

Management fee	0.75%
Performance fee	None
Service fee	0.16%

Legal status

Investment company with variable capital incorporated under Luxembourg law (SICAV)	
Issue structure	Open-end
UCITS V	Yes
Share class	F EUR
This fund is a subfund of Robeco Capital Growth Funds, SICAV	

Registered in

Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Singapore, Spain, Switzerland, United Kingdom

Currency policy

Investments are predominantly made in securities denominated in US dollars. The fund is denominated in euros.

Risk management

Risk management is fully integrated in the investment process to ensure that positions always meet predefined guidelines.

Dividend policy

No dividend is distributed. All returns are reinvested and translated into price gains.

Fund codes

ISIN	LU0832430747
Bloomberg	RUSPGFE LX
Sedol	B93N0L9
WKN	A117UD
Valoren	19568748

Top 10 largest positions

Holdings

JPMorgan Chase & Co
Bank of America Corp
CRH PLC
Johnson & Johnson
Alphabet Inc (Class A)
AbbVie Inc
Corpay Inc
Booking Holdings Inc
Goldman Sachs Group Inc/The
Medtronic PLC
Total

Sector	%
Financials	2.91
Financials	2.51
Materials	2.27
Health Care	2.22
Communication Services	2.00
Health Care	1.98
Financials	1.94
Consumer Discretionary	1.92
Financials	1.89
Health Care	1.88
Total	21.51

Top 10/20/30 weights

TOP 10	21.51%
TOP 20	38.09%
TOP 30	51.03%

Statistics

	3 Years	5 Years
Tracking error ex-post (%)	3.45	3.14
Information ratio	0.20	0.51
Sharpe ratio	0.33	0.93
Alpha (%)	0.75	1.67
Beta	0.98	0.98
Standard deviation	14.72	14.53
Max. monthly gain (%)	11.95	12.33
Max. monthly loss (%)	-8.15	-8.15

Above mentioned ratios are based on gross of fees returns

Hit ratio

	3 Years	5 Years
Months outperformance	17	31
Hit ratio (%)	47.2	51.7
Months Bull market	23	38
Months outperformance Bull	9	16
Hit ratio Bull (%)	39.1	42.1
Months Bear market	13	22
Months Outperformance Bear	8	15
Hit ratio Bear (%)	61.5	68.2

Above mentioned ratios are based on gross of fees returns

Changes

The fund name Robeco US Premium Equities was changed to Robeco BP US Premium Equities, as of 31 August 2016.

Asset Allocation

Asset allocation		
Equity		97.7%
Cash		2.3%

Sector allocation

Activity in the portfolio was minimal in August, with three positions added and no liquidations. New positions came across financials, healthcare and information technology, one in each sector.

Sector allocation		Deviation index	
Financials	<div><div></div></div> 29.7%	<div><div></div></div> 6.7%	
Information Technology	<div><div></div></div> 20.6%	<div><div></div></div> 10.8%	
Health Care	<div><div></div></div> 15.2%	<div><div></div></div> 3.6%	
Industrials	<div><div></div></div> 13.8%	<div><div></div></div> 0.7%	
Consumer Discretionary	<div><div></div></div> 5.9%	<div><div></div></div> -2.2%	
Communication Services	<div><div></div></div> 4.9%	<div><div></div></div> -2.7%	
Consumer Staples	<div><div></div></div> 3.6%	<div><div></div></div> -3.9%	
Energy	<div><div></div></div> 3.5%	<div><div></div></div> -2.6%	
Materials	<div><div></div></div> 2.9%	<div><div></div></div> -1.4%	
Utilities	<div><div></div></div> 0.0%	<div><div></div></div> -4.5%	
Real Estate	<div><div></div></div> 0.0%	<div><div></div></div> -4.5%	

Country allocation

The fund invests only in stocks that are quoted on a US stock exchange.

Country allocation		Deviation index	
United States	<div><div></div></div> 93.4%	<div><div></div></div>	-6.2%
Israel	<div><div></div></div> 2.5%	<div><div></div></div>	2.5%
France	<div><div></div></div> 1.8%	<div><div></div></div>	1.8%
United Kingdom	<div><div></div></div> 1.2%	<div><div></div></div>	1.2%
Denmark	<div><div></div></div> 0.7%	<div><div></div></div>	0.7%
Netherlands	<div><div></div></div> 0.3%	<div><div></div></div>	0.3%
Costa Rica	<div><div></div></div> 0.0%	<div><div></div></div>	0.0%
Gibraltar	<div><div></div></div> 0.0%	<div><div></div></div>	0.0%
Korea	<div><div></div></div> 0.0%	<div><div></div></div>	0.0%
Austria	<div><div></div></div> 0.0%	<div><div></div></div>	0.0%
Hong Kong	<div><div></div></div> 0.0%	<div><div></div></div>	0.0%
Australia	<div><div></div></div> 0.0%	<div><div></div></div>	0.0%
Other	<div><div></div></div> 0.0%	<div><div></div></div>	-0.4%

Currency allocation

N/A

Currency allocation		Deviation index	
U.S. Dollar	95.7%	-4.3%	
Euro	1.8%	1.8%	
Pound Sterling	1.1%	1.1%	
Danish Kroner	0.7%	0.7%	
Israeli Shekel	0.7%	0.7%	

Investment policy

Robeco BP US Premium Equities is an actively managed fund that invests in value stocks in the United States. The selection of these value stocks is based on fundamental analysis. The fund's objective is to achieve a better return than the index. The portfolio is consistently built from the bottom up, to exhibit attractive valuation, strong business fundamentals and improving business momentum. These companies can be large-caps, mid-caps or small-caps.

The fund promotes E&S (i.e. Environmental and Social) characteristics within the meaning of Article 8 of the European Sustainable Finance Disclosure Regulation, integrates sustainability risks in the investment process and applies Robeco's Good Governance policy. The fund applies sustainability indicators, including but not limited to, normative, activity-based and region based exclusions, proxy voting and engagement.

Fund manager's CV

Mr. Ramallo is the Senior Portfolio Manager of the Boston Partners Premium Equity strategy. Previously, he was the assistant portfolio manager of the Boston Partners Small Cap Value strategies. Prior to his portfolio management roles, Mr. Ramallo was a research analyst for Boston Partners. He joined the firm in December 1995 from Deloitte & Touche L.L.P. where he spent three years, most recently at its Los Angeles office. Mr. Ramallo earned a B.A. in Economics/Business from the University of California at Los Angeles and an M.B.A. from the Anderson Graduate School of Management at UCLA. He holds the Chartered Financial Analyst® designation. He is also a Certified Public Accountant (inactive). Mr. Ramallo began his career in the investment industry in 1995.

Fiscal product treatment

The fund is established in Luxembourg and is subject to the Luxembourg tax laws and regulations. The fund is not liable to pay any corporation, income, dividend or capital gains tax in Luxembourg. The fund is subject to an annual subscription tax ('tax d'abonnement') in Luxembourg, which amounts to 0.05% of the net asset value of the fund. This tax is included in the net asset value of the fund. The fund can in principle use the Luxembourg treaty network to partially recover any withholding tax on its income.

Fiscal treatment of investor

The fiscal consequences of investing in this fund depend on the investor's personal situation. For private investors in the Netherlands real interest and dividend income or capital gains received on their investments are not relevant for tax purposes. Each year investors pay income tax on the value of their net assets as at 1 January if and inasmuch as such net assets exceed the investor's tax-free allowance. Any amount invested in the fund forms part of the investor's net assets. Private investors who are resident outside the Netherlands will not be taxed in the Netherlands on their investments in the fund. However, such investors may be taxed in their country of residence on any income from an investment in this fund based on the applicable national fiscal laws. Other fiscal rules apply to legal entities or professional investors. We advise investors to consult their financial or tax adviser about the tax consequences of an investment in this fund in their specific circumstances before deciding to invest in the fund.

MSCI disclaimer

Source MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Morningstar

Copyright © Morningstar Benelux. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For more information on Morningstar, please refer to www.morningstar.com

Sustainalytics disclaimer

The information, methodologies, data and opinions contained or reflected herein are proprietary of Sustainalytics and/or third parties, intended for internal, non-commercial use, and may not be copied, distributed or used in any way, including via citation, unless otherwise explicitly agreed in writing. They are provided for informational purposes only and (1) do not constitute investment advice; (2) cannot be interpreted as an offer or indication to buy or sell securities, to select a project or make any kind of business transactions; (3) do not represent an assessment of the issuer's economic performance, financial obligations nor of its creditworthiness; (4) are not a substitute for a professional advice; (5) past performance is no guarantee of future results. These are based on information made available by third parties, subject to continuous change and therefore are not warranted as to their merchantability, completeness, accuracy or fitness for a particular purpose. The information and data are provided "as is" and reflect Sustainalytics' opinion at the date of their elaboration and publication. Sustainalytics nor any of its third-party suppliers accept any liability for damage arising from the use of the information, data or opinions contained herein, in any manner whatsoever, except where explicitly required by law. Any reference to third party names is for appropriate acknowledgement of their ownership and does not constitute a sponsorship or endorsement by such owner. Insofar as applicable, researched companies referred herein may have a relationship with different Sustainalytics' business units. Sustainalytics has put in place adequate measures to safeguard the objectivity and independence of its opinions. For more information, contact compliance@sustainalytics.com.

Disclaimer

Source: Robeco. As of 31-08-2025, NAV to NAV in denominated currency of the respective share class with dividends re-invested. The performance figures are calculated starting from the first quotation date. ©2025 Morningstar. All Rights Reserved. The information contained here in: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely by Morningstar. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no indication of current or future performance.

This document is not intended as a recommendation or for the purpose of soliciting any action in relation to the Robeco Capital Growth Funds ("Fund") and should not be construed as an offer to sell shares of the Fund (the "Shares") or solicitation by anyone in any jurisdiction in which such an offer or solicitation is not authorised or to any person to whom it is unlawful to make such an offer and solicitation. While all the information prepared in this document is believed to be accurate, the directors of the Fund and its investment manager makes no representation or warranty, whether express or implied, as to the completeness, reliability or accuracy, nor can it accept responsibility for errors appearing in the document. This document does not constitute any recommendation regarding any securities, futures, derivatives or other investment products. Nothing in this document constitutes accounting, legal, regulatory, tax or other advice. Any decision to subscribe for interests in the Fund must be made solely on the basis of information contained in the prospectus (the "Prospectus"), which information may be different from the information contained in this document, and with independent analyses of your investment and financial situation and objectives. The information contained in this document is qualified in its entirety by reference to the Prospectus, and this document should, at all times, be read in conjunction with the Prospectus. Detailed information on the Fund and associated risks is contained in the Prospectus. Any decision to participate in the Fund should be made only after reviewing the sections regarding investment considerations, conflicts of interest, risk factors and the relevant Singapore selling restrictions (as described in the section entitled "Important Information for Singapore Investors") contained in the Prospectus. You should consult your professional adviser if you are in doubt about the stringent restrictions applicable to the use of this document, regulatory status of the Fund, applicable regulatory protection, associated risks and suitability of the Fund to your objectives. This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the Fund and its investment manager to any registration or licensing requirement within such jurisdiction. Investors should note that only the sub-funds listed in the appendix to the section entitled "Important Information for Singapore Investors" of the Prospectus (the "Sub-Funds") are available to Singapore investors. The Sub-Funds are notified as restricted foreign schemes under the Securities and Futures Act, Chapter 289 of Singapore ("SFA") and are invoking the exemptions from compliance with prospectus registration requirements pursuant to the exemptions under Section 304 and Section 305 of the SFA. The Sub-Funds are not authorised or recognised by the Monetary Authority of Singapore and Shares in the Sub-Funds are not allowed to be offered to the retail public in Singapore. The Prospectus of the Fund is not a prospectus as defined in the SFA. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. The Sub-Funds may only be promoted exclusively to persons who are sufficiently experienced and sophisticated to understand the risks involved in investing in such schemes, and who satisfy certain other criteria provided under Section 304, Section 305 or any other applicable provision of the SFA and the subsidiary legislation enacted thereunder. You should consider carefully whether the investment is suitable for you. This document may contain projections or other forward looking statements regarding future events or future financial performance of countries, markets or companies and such projection or forecast is not indicative of the future or likely performance of the Fund. Neither the Fund, its investment manager nor any of their associates, nor any director, officer or employee accepts any liability whatsoever for any loss arising directly or indirectly from the use of this document. The information contained in this document, including any data, projections and underlying assumptions are based upon certain assumptions, management forecasts and analysis of information available as at the date of this document and reflects prevailing conditions and our views as of the date of the document, all of which are accordingly subject to change at any time without notice and the Fund and its investment manager are under no obligation to notify you of any of these changes. Prospective investors should not view the past performance of the Fund or its investment manager as indicative of future results.